Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: The Canadian ESSENCE ST segment monitoring substudy

Journal of the American College of Cardiology

Volumn 36, Issue 5, 2000, Pages 1507-1513

  Goodman, Shaun G ^a,e   Barr, Aiala ^a   Sobtchouk, Anatoli ^a   Cohen, Marc ^b   Fromell, Gregg J ^c   Laperrière, Luc ^d   Hill, Carol ^a   Langer, Anatoly ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c Covance Clinical Trials Research and Development Inc ^*  (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RECURRENCE; SURVIVAL RATE; TIME FACTORS;

EID: 0034332849     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00915-3     Document Type: Article

References (25)

1. Continuous electrocardiographic monitoring in patients with unstable angina pectoris: Identification of high-risk subgroup with severe coronary disease, variant angina, and/or impaired early prognosis
2. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina
3. Prognostic significance of silent myocardial ischemia in patients with unstable angina
4. ST segment shift in unstable angina: Pathophysiology and association with coronary anatomy and hospital outcome
5. Prognostic implications of transient - Predominantly silent - Ischemia in unstable angina pectoris
6. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome
7. Transient ischemia refractory to conventional medical treatment in unstable angina: Angiographic correlates and prognostic implications
8. Relation of severity of symptoms to transient myocardial ischemia and prognosis in unstable angina
9. Early continuous ST segment monitoring in unstable angina: Prognostic value additional to the clinical characteristics and the admission electrocardiogram
10. Pathophysiology of transient myocardial ischemia in acute coronary syndromes. Characterization by continuous ST segment monitoring
11. Silent ischemia predicts infarction and death during 2-year follow-up of unstable angina
12. Long-term prognosis in unstable angina. The importance of early risk stratification using continuous ST segment monitoring
13. Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in patients with unstable angina
14. Importance of thrombosis and thrombolysis in silent ischemia: Comparison of patients with acute myocardial infarction and unstable angina
15. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
16. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
17. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
18. Reactivation of unstable angina after the discontinuation of heparin
19. Low molecular weight heparins
20. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitor
21. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin
22. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial
23. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)
24. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
25. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection